This 30-day trial demonstrated that suspending (n = 334) or continuing (n = 325) these therapies had no effect on the mortality rate of COVID-19 in this population [16,19], suggesting that the indirect increase of ACE2 does not increase intracellular viral load, and is not attributed to severe COVID-19. This evidence concerns the gene ACE2 and COVID-19.